Literature DB >> 19347386

Glutamine attenuates nitric oxide synthase expression and mitochondria membrane potential decrease in interleukin-1beta-activated rat hepatocytes.

Jun Lu1, Xin-ying Wang, Wen-hao Tang.   

Abstract

BACKGROUND: Mitochondrial dysfunction induced by nitric oxide (NO) overproduction is involved in the pathogenesis of organ failure during many severe diseases. Recently, several experiments have reported that glutamine (Gln) modifies inducible nitric oxide synthase (iNOS) gene expression which is thought to be responsible for its beneficial effects in critical illnesses. AIM OF THE STUDY: This study was designed to evaluate the effects of Gln on NO production, iNOS expression and mitochondria membrane potential (Deltapsim) variation in interleukin (IL)-1beta-activated rat hepatocytes. The mechanical effects of nuclear factor kappaB (NF-kappaB) were also investigated.
METHODS: Primary cultured rat hepatocytes were isolated by an in situ collagenase perfusion method. The cultured hepatocytes were treated with IL-1beta (1 nmol/l) alone or with Gln in concentrations ranging from 2 to 10 mmol/l for 24 h. The concentrations of alanine aminotransferase (ALT) and nitrite in the culture medium were detected by biochemical methods. The levels of iNOS protein and mRNA in the hepatocytes were analyzed by western blot and real-time RT-PCR. The Deltapsim of the hepatocytes was assessed with flow cytometry after incubating with fluorescent probe JC-1. Th binding activity of NF-kappaB in hepatocytes was investigated using electrophoretic mobility shift assay.
RESULTS: IL-1beta significantly enhanced iNOS protein and mRNA level in the cultured rat hepatocytes which consisted with the increased NO production and ALT releasing in the culture medium. These effects were inhibited by the treatment of glutamine in a dose-dependent manner. The Deltapsim of hepatocytes was markedly decreased after IL-1beta stimulation which was significantly attenuated by Gln at 5 and 10 mmol/l. NF-kappaB activity was increased by IL-1beta stimulation and this effect was augmented by Gln at 5 and 10 mol/l.
CONCLUSIONS: These observations indicate that Gln has a capability to protect mitochondria function in hepatocytes under inflammatory stress. Although the molecular mechanism remains to be clarified, our findings suggest this effect may be related to down-regulation of iNOS gene expression through an NF-kappaB independent pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19347386     DOI: 10.1007/s00394-009-0018-x

Source DB:  PubMed          Journal:  Eur J Nutr        ISSN: 1436-6207            Impact factor:   5.614


  24 in total

Review 1.  Biology of nitric oxide signaling.

Authors:  L Liaudet; F G Soriano; C Szabó
Journal:  Crit Care Med       Date:  2000-04       Impact factor: 7.598

Review 2.  Cytopathic hypoxia. Mitochondrial dysfunction as mechanism contributing to organ dysfunction in sepsis.

Authors:  M P Fink
Journal:  Crit Care Clin       Date:  2001-01       Impact factor: 3.598

3.  Alanine-glutamine dipeptide (AGD) inhibits expression of inflammation-related genes in hemorrhagic shock.

Authors:  Rongjie Yang; Xiaoyu Tan; Ann M Thomas; Robert Steppacher; Nilofer Qureshi; David C Morrison; Charles W Van Way
Journal:  JPEN J Parenter Enteral Nutr       Date:  2007 Jan-Feb       Impact factor: 4.016

4.  Six-month outcome of critically ill patients given glutamine-supplemented parenteral nutrition.

Authors:  R D Griffiths; C Jones; T E Palmer
Journal:  Nutrition       Date:  1997-04       Impact factor: 4.008

Review 5.  Novel roles of nitric oxide in hemorrhagic shock.

Authors:  C Szabó; T R Billiar
Journal:  Shock       Date:  1999-07       Impact factor: 3.454

6.  Association between mitochondrial dysfunction and severity and outcome of septic shock.

Authors:  David Brealey; Michael Brand; Iain Hargreaves; Simon Heales; John Land; Ryszard Smolenski; Nathan A Davies; Chris E Cooper; Mervyn Singer
Journal:  Lancet       Date:  2002-07-20       Impact factor: 79.321

7.  Age-related decline of inducible nitric oxide synthase gene expression in primary cultured rat hepatocytes.

Authors:  Jae-Eun Pie; Soo-Youn Baek; Hong-Pyo Kim; Seung-Duk Ryu; Woon-Gye Chung; Young-Nam Cha; Chang-Shin Park
Journal:  Mol Cells       Date:  2002-06-30       Impact factor: 5.034

Review 8.  Glutamine supplementation in serious illness: a systematic review of the evidence.

Authors:  Frantisek Novak; Daren K Heyland; Alison Avenell; John W Drover; Xiangyao Su
Journal:  Crit Care Med       Date:  2002-09       Impact factor: 7.598

9.  Mitochondrial dysfunction in a long-term rodent model of sepsis and organ failure.

Authors:  David Brealey; Sekhar Karyampudi; Thomas S Jacques; Marco Novelli; Ray Stidwill; Val Taylor; Ryszard T Smolenski; Mervyn Singer
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2003-11-06       Impact factor: 3.619

10.  Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock.

Authors:  Angel López; Jose Angel Lorente; Jay Steingrub; Jan Bakker; Angela McLuckie; Sheila Willatts; Michael Brockway; Antonio Anzueto; Laurent Holzapfel; Desmond Breen; Michael S Silverman; Jukka Takala; Jill Donaldson; Carl Arneson; Geraldine Grove; Steven Grossman; Robert Grover
Journal:  Crit Care Med       Date:  2004-01       Impact factor: 7.598

View more
  3 in total

Review 1.  Computational analysis of high-throughput flow cytometry data.

Authors:  J Paul Robinson; Bartek Rajwa; Valery Patsekin; Vincent Jo Davisson
Journal:  Expert Opin Drug Discov       Date:  2012-06-18       Impact factor: 6.098

2.  Protective effect of glutamine in critical patients with acute liver injury.

Authors:  Hai-Bin Ni; Zheng Zhang; Hai-Dong Qin
Journal:  World J Emerg Med       Date:  2011

Review 3.  Experimental treatments for mitochondrial dysfunction in sepsis: A narrative review.

Authors:  Guilang Zheng; Juanjuan Lyu; Jingda Huang; Dan Xiang; Meiyan Xie; Qiyi Zeng
Journal:  J Res Med Sci       Date:  2015-02       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.